Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228-47, 2009 46. Safety profile of recombinant poxviral TRICOM vaccines. 2013 ASCO Annual Meeting 31:abstr e16036, 2013 47. Wolchok JD, Hoos A, O'Day S, et al: Guidelines for the evaluation of immune therapy activity in solid tumors: immune -related response criteria. Clin Cancer Res 15:7412-20, 2009 59 Abbreviated Title: Phase I MVA -Brachyury -TRICOM Version Date: September 14, 2016 Confidential 48. Choi H, Charnsangavej C, Faria SC, et al: Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25:1753-9, 2007 49. Choi H: Response evaluation of gastrointestinal stromal tumors. Oncologist 13 Suppl 2:4-7, 2008 50. Stacchiotti S, Collini P, Messina A, et al: High -grade soft -tissue sarcomas: tumor response assessment --pilot study to assess th e correlation between radiologic and pathologic response by using RECIST and Choi criteria. Radiology 251:447-56, 2009 51. Smith AD, Shah SN, Rini BI, et al: Utilizing pre -therapy clinical schema and initial CT changes to predict progression- free survival in patients with metastatic renal cell carcinoma on VEGF -targeted therapy: A preliminary analysis. Urol Oncol, 2011 60 Abbreviated Title: Phase I MVA -Brachyury -TRICOM Version Date: September 14, 2016 Confidential 13 APPENDICES 13.1 APPENDIX A: PERFORMANCE STATUS CRITERIA ECOG Performance Status Scale Karnofsky Performance Scale Grade Descriptions Percent Description 0 Normal activity. Fully active, able to carry on all pre- disease performance without restriction.